The Election Committee has carefully selected the following candidates from the nominations, using criteria based on qualifications, experience, and dedication to our Society. We firmly believe that each of them possesses the necessary skills and expertise to guide EAS towards continued success.
The new member will be replacing the retiring member Prof Philippe Moulin (2020-2023) from January 2024.
We are pleased to announce the following candidates:
- Professor Kirsten Holven, Norway
- Professor Ulrich Laufs, Germany
- Professor Evangelos Liberopoulos, Greece
- Professor Isabella Sudano, Switzerland
We invite all EAS members to take part in the life of the Society by using their vote. Elections will be held through an online ballot June 1 – June 30.
Thank you in advance for your participation!
Professor Kirsten Holven
Department of Nutrition, Institute for basic medical sciences, Faculty of Medicine, University of Oslo
Biography
Professor Kirsten B. Holven is head of section of clinical nutrition, department of nutrition, University of Oslo and a researcher at the National Advisory Unit on Familial Hypercholesterolemia (FH), Oslo University Hospital.
She has worked with research relating to patients with FH, for more than 25 years with particular focus on impact on cholesterol exposure in children with FH and women´s health issues focusing on women with FH, pregnancy and breastfeeding related issues, lipids through life cycle and dietary intervention studies.
She is leading the education committee for the five-year master program in clinical nutrition at the department of nutrition, faculty of medicine and at the national advisory unit on FH, she is involved in organising national educational lipid meetings and making information material for both health personal and patients. She collaborates with the Norwegian FH patient organisation and is member of the scientific advisory committee of the European FH patient organisation. She is the national contact person for the EAS Lipid Clinic Network and national lead of Norway for the EAS FHSC. She has been part of the scientific programme committee of the Scandinavian Society of Atherosclerosis Research annual meeting; is part of the EAS Scientific Programme Committee 2024 and is in the organising committee of the EAS Pediatric meeting 2023. She is a member of the Norwegian national nutrition council.
Current positions
(Information on all positions, both within companies and other Societies)
Companies
- None
Other Societies
- EAS Scientific Programme Committee 2024
- In organising committee of the EAS Pediatric meeting 2023
- Member of the Norwegian national nutrition council
- Head of research at the Norwegian national advisory unit on FH; a governmental financed organisation
- Member of Scientific advisory committee for FH Europe
Maintaining Integrity in EAS Scientific and Clinical Activities
EAS manages conflicts of interest to maintain integrity in scientific and clinical activities organized by its members. This includes guidelines, consensus papers, journals, congresses, and educational content. Please see the complete disclosure of potential conflicts of interest below.
Log in to view full COI disclosure
Professor Ulrich Laufs
Chief of Cardiology and Interventional Cardiologist at Leipzig University Hospital
Professor of Cardiology at Leipzig University, Germany
Biography
After completing his training at the Universities of Bochum and Hamburg, he was resident at the University of Cologne and spent 2 years as post-doctoral researcher at the Cardiovascular Division of the Brigham and Women’s Hospital in Boston, USA. Since that time, Professor Laufs has published multiple experimental and clinical studies on the regulation of cardiovascular function by lipoproteins and lipid-modifying medications. Subsequently, he also undertook fellowships at the Universities of Cologne and the Saarland. Before moving to Leipzig in 2017, he was Professor for Clinical and Experimental Medicine and Vice-chairman of the Department of Internal Medicine, Cardiology, Angiology and Intensive Medicine at the University of Saarland in Homburg, Germany.
Professor Laufs heads a research group focused on cellular and molecular mechanisms, and clinical studies of cardiovascular prevention with a special interest in lipid disorders. His group has > 500 publications listed medline that have been cited >33,500 times (H-index 85).
Laufs serves as elected member of the board of the German Society of Cardiology, spokesperson of the D•A•CH-Gesellschaft Herz-Kreislauf-Prävention, member of the federal drug commissions of the German Physicians and German Pharmacists and in several editorial boards of cardiovascular journals. Professor Laufs has received numerous honours, including a first place in the Young Investigator Award of the American College of Cardiology, the Population Sciences Award of the European Society of Cardiology, the Paul Martini Award, and the Albert Fraenkel Award of the German Cardiac Society. He is proud member of the EAS for more than a decade participating in multiple EAS activities including consensus papers, commitees, educational activities and serving as co-chair of the German FH-registry (CaReHigh) and in the progam comitee of the 2023 EAS scientific conference.
Vision Statement
My main three goals in the EAS Executive committee would be to
- Strengthen the influence of ALL national societies within the EAS and to significantly broaden the number of individuals that are actively involved.
- To develop the EAS homepage to a major resource on atherosclerotic diseases in Europe. My vision is to jointly work towards a platform that provides modern content on the full spectrum from basic science to clinical care. I believe that the opportunity is to structure the content already available within the society. Written materials need to be enhanced and connected with modern graphics, web- /podcasts, social media content, and state-of-the art CME. I believe that we can derive significant potential from the contents of our scientific meeting and, importantly, and through our journal, Atherosclerosis. At the same time, my vision for the digital activities is to support both the EAS meeting and to increase the visibility and impact factor of the Journal.
- To use the joint expertise and power of the EAS membership to address national and European policy makers, e.g. with regard to cholesterol screening programs, research funding or European standards for laboratory testing.
Current positions
(Information on all positions, both within companies and other Societies)
Companies
- None
Other Societies
- Chair of Cardiology, Leipzig University; Chief of Cardiology, Leipzig University Hospital
- Elected member of the executive board, German Cardiac Society (DGK)
- Elected spokesperson of the executive board, D•A•CH-Gesellschaft Herz-Kreislauf-Prävention
Maintaining Integrity in EAS Scientific and Clinical Activities
EAS manages conflicts of interest to maintain integrity in scientific and clinical activities organized by its members. This includes guidelines, consensus papers, journals, congresses, and educational content. Please see the complete disclosure of potential conflicts of interest below.
Log in to view full COI disclosure
Professor Evangelos Liberopoulos
University of Athens, Greece
Biography
Prof Evangelos Liberopoulos is an Internist-Lipidologist-Diabetologist. He was born in Athens in 1972. He graduated from the University of Ioannina Medical School, Ioannina, Greece. He specialized in lipid disorders and cardiovascular disease prevention at the Royal Free Hospital, UCL, London, UK, and in diabetes at the Diabetology Centre of ‘Laikon’ General Hospital of Athens.
He currently serves as a Professor of Medicine-Metabolic Diseases in the School of Medicine, National and Kapodistrian University of Athens, Greece, and 1st Propedeutic Department of Medicine, General Hospital of Athens ‘Laiko’. His main academic and clinical interests include dyslipidemia, atherosclerosis, cardiovascular disease prevention and diabetes. He has published 280 papers in international peer-reviewed journals with >10,000 citations and an H factor of 56.
Prof Liberopoulos is a member of the writing committee for guidelines issued by the Hellenic Diabetes Association and the Hellenic Atherosclerosis Society. He has given over 500 talks in national and international meetings on topics related to cardiovascular disease prevention. He is the principal investigator of several large, randomized trials in lipids and cardiovascular disease prevention. He was the National Lead Investigator for the ODYSSEY OUTOMES trial. He is currently the National Leader for the HELLAS-FH registry and member of the Steering Committee of Familial Hypercholesterolemia Studies Collaboration (FHSC).
As member of the Executive Committee (2010-today) and past-president of the Hellenic Atherosclerosis Society (HAS) (2019-2022), Prof Liberopoulos has co-organised several scientific activities with EAS. He worked closely and successfully with EAS for Athens to be nominated as host of the 2026 EAS Congress.
Current positions
(Information on all positions, both within companies and other Societies)
Companies
- None
Other Societies
- Hellenic Atherosclerosis Society (past president 2019-2022, member of the EC 2023-)
Maintaining Integrity in EAS Scientific and Clinical Activities
EAS manages conflicts of interest to maintain integrity in scientific and clinical activities organized by its members. This includes guidelines, consensus papers, journals, congresses, and educational content. Please see the complete disclosure of potential conflicts of interest below.
Log in to view full COI disclosure
Professor Isabella Sudano
University Heart Centre Cardiology, University Hospital of Zurich, Switzerland
Personal statement
I am a Specialist in internal medicine with special education in arterial hypertension, dyslipidemia and smoking cessation and a PhD in cardiovascular research.
Actual I’m head of the outpatients facilities for hypertension, dyslipidemia and smoking cessation consultation at the Cardiology Unit of the University Hospital of Zurich and Professor at the medical faculty of the University of Zurich.
I have been president of Swiss Society for Hypertension (2018-2021), and I am the incoming president of the Swiss society of Hypertension and of the ESC Council for Hypertension.
I sincerely believe that prevention is the best medicine and working to improve prevention of cardiovascular disease by education subjects/patients and early diagnostic and treatment of cardiovascular risk.
My research topic are mainly focusing on vascular research (endothelial function in the micro and macro circulation, vascular compliance and atherosclerotic changes in the carotid).
Current positions
(Information on all positions, both within companies and other Societies)
- Chief of service and head of clinical research group
- Chief of service and head of the Hypertension, Dyslipidemia and Smoking councelling service
Other Societies
- European Society of Cardiology (FESC and Nucleus member of the ESC Council for hypertension, 2022-2024 Vice President and president elected)
- Swiss Working Group on Lipid and Atherosclerosis (AGLA) incoming president
- Swiss society of hypertension (nucleus member and past president)
- International Society of Hypertesion
- European Society of Hypertension, Italian Society of Hypertension, Swiss Society of Cardiology, Swiss Society of Microcirculation
Maintaining Integrity in EAS Scientific and Clinical Activities
EAS manages conflicts of interest to maintain integrity in scientific and clinical activities organized by its members. This includes guidelines, consensus papers, journals, congresses, and educational content. Please see the complete disclosure of potential conflicts of interest below.
Log in to view full COI disclosure